Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by L. E. Porter
DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
Related publications
Safety, Tolerability and Sustained Weight Loss Over 2 Years With the Once-Daily Human GLP-1 Analog, Liraglutide
International Journal of Obesity
Nutrition
Endocrinology
Dietetics
Medicine
Metabolism
Diabetes
RYGB Produces More Sustained Body Weight Loss and Improvement of Glycemic Control Compared With VSG in the Diet-Induced Obese Mouse Model
Obesity Surgery
Nutrition
Endocrinology
Dietetics
Surgery
Metabolism
Diabetes
Improved Treatment Satisfaction and Weight-Related Quality of Life With Exenatide Once Weekly or Twice Daily
Diabetic Medicine
Internal Medicine
Endocrinology
Metabolism
Diabetes
Exenatide Extended-Release: A Once Weekly Treatment for Patients With Type 2 Diabetes
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal Medicine
Pharmacology
A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
Advances in Therapy
Medicine
Pharmacology
Once-Weekly Exenatide as Adjunct Treatment of Type 1 Diabetes Mellitus in Patients Receiving Continuous Subcutaneous Insulin Infusion Therapy
Canadian Journal of Diabetes
Internal Medicine
Endocrinology
Metabolism
Medicine
Diabetes
Adherence to Liraglutide Once Daily or Exenatide Once Weekly Over a 12-Month Period Among Commercially Insured Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Family Support and Weight-Loss Strategies Among Adolescents Reporting Sustained Weight Loss
Public Health Nutrition
Nutrition
Dietetics
Public Health
Environmental
Medicine
Occupational Health
Exenatide Once-Weekly Injection for the Treatment of Type 2 Diabetes in Chinese Patients: Current Perspectives
Therapeutics and Clinical Risk Management